Genetic polymorphisms in the Paraoxonase 1 gene and risk of ovarian epithelial carcinoma

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 8, 2008, Pages 2070-2077

  Lurie, Galina ^a   Wilkens, Lynne R ^a   Thompson, Pamela J ^a   McDuffie, Katharine E ^a   Carney, Michael E ^b   Terada, Keith Y ^b   Goodman, Marc T ^a  

^a UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^b UNIVERSITY OF HAWAII   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1;

ADULT; AGED; ALLELE; ARTICLE; BLOOD SAMPLING; CANCER RISK; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; ETHNICITY; FEMALE; GENE; GENETIC POLYMORPHISM; GENOTYPE; HISTOLOGY; HUMAN; HUMAN TISSUE; INTERVIEW; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; OBESITY; OVARY CARCINOMA; PARAOXONASE 1 GENE; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLELES; ARYLDIALKYLPHOSPHATASE; CASE-CONTROL STUDIES; DNA DAMAGE; FEMALE; GENOTYPE; HAWAII; HUMANS; INTERVIEWS AS TOPIC; LOGISTIC MODELS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; OXIDATIVE STRESS; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK; SEER PROGRAM;

EID: 54049101738     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-0145     Document Type: Article

References (57)

1. Ness RB, Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst 1999;91:1459-67.
2. Murdoch WJ, McDonnel AC. Roles of the ovarian surface epithelium in ovulation and carcinogenesis. Reproduction 2002;123:743-50.
3. Murdoch WJ, Martinchick JF. Oxidative damage to DNA of ovarian surface epithelial cells affected by ovulation: carcinogenic implication and chemoprevention. Exp Biol Med (Maywood) 2004;229:546-52.
4. Behrman HR, Kodaman PH, Preston SL, Gao S. Oxidative stress and the ovary. J Soc Gynecol Investig 2001;8:S40-2.
5. Agarwal A, Gupta S, Sharma RK. Role of oxidative stress in female reproduction. Reprod Biol Endocrinol 2005;3:28.
6. Goldstein BD, Witz G. Free radicals and carcinogenesis. Free Radic Res Commun 1990;11:3-10.
7. Cejas P, Casado E, Belda-Iniesta C, et al. Implications of oxidative stress and cell membrane lipid peroxidation in human cancer (Spain). Cancer Causes Control 2004;15:707-19.
8. Lau AT, Wang Y, Chiu JF. Reactive oxygen species: current knowledge and applications in cancer research and therapeutic. J Cell Biochem 2008;104:657-67.
9. Behrend L, Henderson G, Zwacka RM. Reactive oxygen species in oncogenic transformation. Biochem Soc Trans 2003;31:1441-4.
10. Murdoch WJ. Carcinogenic potential of ovulatory genotoxicity. Biol Reprod 2005;73:586-90.
11. Olson SH, Carlson MD, Ostrer H, et al. Genetic variants in SOD2, MPO, and NQO1, and risk of ovarian cancer. Gynecol Oncol 2004;93:615-20.
12. Goodman MT, McDuffie K, Kolonel LN, et al. Case-control study of ovarian cancer and polymorphisms in genes involved in catecholestrogen formation and metabolism. Cancer Epidemiol Biomarkers Prev 2001;10:209-16.
13. Garner EI, Stokes EE, Berkowitz RS, Mok SC, Cramer DW. Polymorphisms of the estrogen-metabolizing genes CYP17 and catechol-O-methyltransferase and risk of epithelial ovarian cancer. Cancer Res 2002;62:3058-62.
14. Ng CJ, Shih DM, Hama SY, Villa N, Navab M, Reddy ST. The paraoxonase gene family and atherosclerosis. Free Radic Biol Med 2005;38:153-63.
15. Teiber JF, Billecke SS, La Du BN, Draganov DI. Estrogen esters as substrates for human paraoxonases. Arch Biochem Biophys 2007;461:24-9.
16. Blatter Garin MC, Abbott C, Messmer S, et al. Quantification of human serum paraoxonase by enzyme-linked immunoassay: population differences in protein concentrations. Biochem J 1994;304:549-54.
17. Droge W. Free radicals in the physiological control of cell function. Physiol Rev 2002;82:47-95.
18. Motta M, Pistone G, Franzone AM, et al. Antibodies against ox-LDL serum levels in patients with hepatocellular carcinoma. Panminerva Med 2003;45:69-73.
19. Delimaris I, Faviou E, Antonakos G, Stathopoulou E, Zachari A, Onyssiou-Asteriou A. Oxidized LDL, serum oxidizability and serum lipid levels in patients with breast or ovarian cancer. Clin Biochem 2007;40:1129-34.
20. Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 2001;21:473-80.
21. National Center for Biotechnology Information database. 1-10-2008; NCBI Web site.
22. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 1993;3:73-6.
23. Garin MC, James RW, Dussoix P, et al. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest 1997;99:62-6.
24. Adkins S, Gan KN, Mody M, La Du BN. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 1993;52:598-608.
25. Davies HG, Richter RJ, Keifer M, Broomfield CA, Sowalla J, Furlong CE. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet 1996;14:334-6.
26. Leviev I, Negro F, James RW. Two alleles of the human paraoxonase gene produce different amounts of mRNA. An explanation for differences in serum concentrations of paraoxonase associated with the (Leu-Met54) polymorphism. Arterioscler Thromb Vasc Biol 1997;17:2935-9.
27. Leviev I, James RW. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol 2000;20:516-21.
28. Leviev I, Deakin S, James RW. Decreased stability of the M54 isoform of paraoxonase as a contributory factor to variations in human serum paraoxonase concentrations. J Lipid Res 2001;42:528-35.
29. Ruiz J, Blanche H, James RW, et al. Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet 1995;346:869-72.
30. Akcay MN, Yilmaz I, Polat MF, Akcay G. Serum paraoxonase levels in gastric cancer. Hepatogastroenterology 2003;50 Suppl 2:cclxxiii-cclxxv.
31. Akcay MN, Polat MF, Yilmaz I, Akcay G. Serum paraoxonase levels in pancreatic cancer. Hepatogastroenterology 2003;50 Suppl 2:ccxxv-ccxxvii.
32. Elkiran ET, Mar N, Aygen B, Gursu F, Karaoglu A, Koca S. Serum paraoxonase and arylesterase activities in patients with lung cancer in a Turkish population. BMC Cancer 2007;7:48.
33. Stevens VL, Rodriguez C, Pavluck AL, Thun MJ, Calle EE. Association of polymorphisms in the paraoxonase 1 gene with breast cancer incidence in the CPS-II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev 2006;15:1226-8.
34. Gallicchio L, McSorley MA, Newschaffer CJ, et al. Body mass, polymorphisms in obesity-related genes, and the risk of developing breast cancer among women with benign breast disease. Cancer Detect Prev 2007;31:95-101.
35. Antognelli C, Mearini L, Talesa VN, Giannantoni A, Mearini E. Association of CYP17, GSTP1, and PON1 polymorphisms with the risk of prostate cancer. Prostate 2005;63:240-51.
36. Lee CH, Lee KY, Choe KH, et al. Effects of oxidative DNA damage induced by polycyclic aromatic hydrocarbons and genetic polymorphism of the paraoxonase-1 (PON1) gene on lung cancer. J Prev Med Pub Health 2005;38:345-50.
37. Kerridge I, Lincz L, Scorgie F, Hickey D, Granter N, Spencer A. Association between xenobiotic gene polymorphisms and non-Hodgkin's lymphoma risk. Br J Haematol 2002;118:477-81.
38. Lincz LF, Kerridge I, Scorgie FE, Bailey M, Enno A, Spencer A. Xenobiotic gene polymorphisms and susceptibility to multiple myeloma. Haematologica 2004;89:628-9.
39. Costa LG, Cole TB, Furlong CE. Paraoxonase (PON1): from toxicology to cardiovascular medicine. Acta Biomed 2005;76 Suppl 2:50-7.
40. Scheffler E, Wiest E, Woehrle J, et al. Smoking influences the atherogenic potential of low-density lipoprotein. Clin Investig 1992;70:263-8.
41. Isik B, Ceylan A, Isik R. Oxidative stress in smokers and nonsmokers. Inhal Toxicol 2007;19:767-9.
42. Ferretti G, Bacchetti T, Moroni C, et al. Paraoxonase activity in high-density lipoproteins: a comparison between healthy and obese females. J Clin Endocrinol Metab 2005;90:1728-33.
43. Surveillance, Epidemiology, and End Results Program. Summary staging guide for the cancer Surveillance, Epidemiology, and End Results Reporting (SEER) Program. Bethesda (MD): U.S. Department of Health and Human Services, USPHS, NIH, 1986.
44. Oyama N, Johnson DB. Hawaii health surveillance program survey methods and procedures. R&S Report 54. Honolulu (HI): State Department of Health Research and Statistics Office; 1986.
45. Tung KH, Goodman MT, Wu AH, et al. Reproductive factors and epithelial ovarian cancer risk by histologic type: a multiethnic case-control study. Am J Epidemiol 2003;158:629-38.
46. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263-5.
47. Van Der Logt EM, Janssen CH, Van HZ, et al. No association between genetic polymorphisms in NAD(P)H oxidase p22phox and paraoxonase 1 and colorectal cancer risk. Anticancer Res 2005;25:1465-70.
48. Wheeler JG, Keavney BD, Watkins H, Collins R, Danesh J. Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. Lancet 2004;363:689-95.
49. Mackness MI, Arrol S, Mackness B, Durrington PN. Alloenzymes of paraoxonase and effectiveness of high-density lipoproteins in protecting low-density lipoprotein against lipid peroxidation. Lancet 1997;349:851-2.
50. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 1998;101:1581-90.
51. Ness RB, Grisso JA, Cottreau C, et al. Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. Epidemiology 2000;11:111-7.
52. Bhattacharyya T, Nicholls SJ, Topol EJ, et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 2008;299:1265-76.
53. Verit FF, Erel O, Celik N. Serum paraoxonase-1 activity in women with endometriosis and its relationship with the stage of the disease. Hum Reprod 2008;23:100-4.
54. Fenkci IV, Serteser M, Fenkci S, Kose S. Paraoxonase levels in women with polycystic ovary syndrome. J Reprod Med 2007;52:879-83.
55. Thomann R, Rossinelli N, Keller U, et al. Differences in low-grade chronic inflammation and insulin resistance in women with previous gestational diabetes mellitus and women with polycystic ovary syndrome. Gynecol Endocrinol 2008;24:199-206.
56. Schildkraut JM, Schwingl PJ, Bastos E, Evanoff A, Hughes C. Epithelial ovarian cancer risk among women with polycystic ovary syndrome. Obstet Gynecol 1996;88:554-9.
57. Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 1996;33:498-507.